GLPwatch
Saxenda for MASH (metabolic dysfunction-associated steatohepatitis)
liraglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCSaxenda (liraglutide) is not FDA-approved for MASH (metabolic dysfunction-associated steatohepatitis). Research includes a phase 2 study (LEAN) and multiple trials showing effects on liver fat and steatosis, but these findings are investigational and not conclusive for approval.
AI summary of the sources below.
| Drug | Saxenda (liraglutide) |
|---|---|
| Condition | MASH (metabolic dysfunction-associated steatohepatitis) |
| Approval status | Investigational / off-label |
| Research papers | 50 |
Saxenda is not FDA-approved for mash (metabolic dysfunction-associated steatohepatitis); the research below reflects investigational or off-label study only.
Research on liraglutide for mash (metabolic dysfunction-associated steatohepatitis) (50)
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.
- Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.
- Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.
- Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy.
- Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.
- Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
- Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
- Liraglutide modulates gut microbiota and reduces NAFLD in obese mice.
- The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.
- Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.
- Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.
- Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease.
- The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
- Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans.
- Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
- Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.
- Liraglutide: the therapeutic promise from animal models.
- Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.
- Liraglutide attenuates hepatic iron levels and ferroptosis in db/db mice.
- Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice.
- Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.
- Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis.
- Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.